Clinical Trial Update: A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating SI-B003 alone or in combination with BL-B01D1 for unresectable locally advanced or recurrent metastatic HER2-negative breast c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• BL-B01D1
• SI-B003

Snippet

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Conditions: Breast Cancer | Phase 2 | Status: RECRUITING